Biodesix PE Ratio 2020-2025 | BDSX
Current and historical p/e ratio for Biodesix (BDSX) from 2020 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biodesix PE ratio as of June 25, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Biodesix PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-25 | 0.27 | 0.00 | |
| 2025-03-31 | 0.63 | $-0.29 | 0.00 |
| 2024-12-31 | 1.53 | $-0.35 | 0.00 |
| 2024-09-30 | 1.78 | $-0.39 | 0.00 |
| 2024-06-30 | 1.53 | $-0.46 | 0.00 |
| 2024-03-31 | 1.43 | $-0.55 | 0.00 |
| 2023-12-31 | 1.84 | $-0.65 | 0.00 |
| 2023-09-30 | 1.65 | $-0.90 | 0.00 |
| 2023-06-30 | 1.23 | $-1.10 | 0.00 |
| 2023-03-31 | 1.86 | $-1.33 | 0.00 |
| 2022-12-31 | 2.30 | $-1.59 | 0.00 |
| 2022-09-30 | 1.27 | $-1.73 | 0.00 |
| 2022-06-30 | 1.64 | $-1.80 | 0.00 |
| 2022-03-31 | 1.69 | $-1.81 | 0.00 |
| 2021-12-31 | 5.29 | $-1.57 | 0.00 |
| 2021-09-30 | 8.22 | $-1.33 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.040B | $0.071B |
| Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The company also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. Biodesix Inc. is based in Boulder, Colorado. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $141.323B | 26.51 |
| CVS Health (CVS) | United States | $85.490B | 10.63 |
| Elevance Health (ELV) | United States | $85.046B | 10.97 |
| Cencora (COR) | United States | $57.007B | 19.83 |
| Natera (NTRA) | United States | $23.468B | 0.00 |
| DiDi Global (DIDIY) | China | $23.015B | 24.45 |
| Labcorp Holdings (LH) | United States | $21.974B | 17.82 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.262B | 0.00 |
| Solventum (SOLV) | United States | $12.973B | 13.73 |
| CochLear (CHEOY) | Australia | $12.633B | 0.00 |
| ICON (ICLR) | Ireland | $11.996B | 11.15 |
| Revvity (RVTY) | United States | $11.361B | 19.55 |
| Viatris (VTRS) | United States | $10.504B | 3.61 |
| Avantor (AVTR) | United States | $9.172B | 13.33 |
| Medpace Holdings (MEDP) | United States | $9.062B | 24.07 |
| HealthEquity (HQY) | United States | $9.009B | 39.46 |
| Sonic Healthcare (SKHHY) | Australia | $8.263B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.289B | 14.28 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.259B | 25.08 |
| BrightSpring Health Services (BTSG) | United States | $4.024B | 36.92 |
| Sotera Health (SHC) | United States | $3.191B | 18.13 |
| Alignment Healthcare (ALHC) | United States | $2.786B | 0.00 |
| Concentras Parent (CON) | United States | $2.716B | 15.70 |
| Surgery Partners (SGRY) | United States | $2.705B | 35.18 |
| GeneDx Holdings (WGS) | United States | $2.594B | 99.89 |
| Organon (OGN) | United States | $2.587B | 2.75 |
| PACS (PACS) | United States | $1.928B | 0.00 |
| Ardent Health (ARDT) | United States | $1.887B | 8.04 |
| Progyny (PGNY) | United States | $1.822B | 40.11 |
| GoodRx Holdings (GDRX) | United States | $1.811B | 36.21 |
| Premier (PINC) | United States | $1.791B | 13.59 |
| Teladoc Health (TDOC) | United States | $1.403B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.158B | 8.81 |
| CareDx (CDNA) | United States | $1.051B | 16.42 |
| Establishment Labs Holdings (ESTA) | $1.034B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.999B | 0.00 |
| Agilon Health (AGL) | United States | $0.915B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.840B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.831B | 7.78 |
| Nutex Health (NUTX) | United States | $0.641B | 9.70 |
| LifeMD (LFMD) | United States | $0.639B | 0.00 |
| Embecta (EMBC) | United States | $0.597B | 4.02 |
| InnovAge Holding (INNV) | United States | $0.545B | 0.00 |
| Enhabit (EHAB) | United States | $0.482B | 39.62 |
| Sonida Senior Living (SNDA) | United States | $0.463B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.463B | 10.42 |
| SBC Medicals (SBC) | United States | $0.442B | 0.00 |
| Omada Health (OMDA) | $0.404B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.298B | 0.00 |
| Beauty Health (SKIN) | United States | $0.242B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.237B | 0.00 |
| Oncology Institute (TOI) | United States | $0.210B | 0.00 |
| DocGo (DCGO) | United States | $0.176B | 28.83 |
| So-Young (SY) | China | $0.174B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.123B | 0.00 |
| OncoCyte (IMDX) | United States | $0.099B | 0.00 |
| KindlyMD (NAKA) | United States | $0.092B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.076B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.055B | 0.00 |
| ModivCare (MODV) | United States | $0.046B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |